Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Comparative Trial of the Efficacy and Safety of Different Dosages in Sequential Therapy With Mexidol® in Patients With Primary Open-angle Glaucoma

NCT06903156 is registered in ClinicalTrials.gov with Pharmasoft as lead sponsor.

NCT NCT06903156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06903156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Comparative Trial of the Efficacy and Safety of Different Dosages in Sequential Therapy With Mexidol® in Patients With Primary Open-angle Glaucoma
Lead sponsor
Pharmasoft
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2021
Completion date
September 7, 2023
Enrollment
102 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary open-angle glaucoma (poag)